<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00427791</url>
  </required_header>
  <id_info>
    <org_study_id>2004-0989</org_study_id>
    <nct_id>NCT00427791</nct_id>
  </id_info>
  <brief_title>Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia</brief_title>
  <official_title>Phase II Randomized Study Evaluating the Addition of Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:

        -  To determine the progression free survival (PFS) of the preparative regimen rituximab,
           etoposide and total body irradiation (TBI), in patients with acute lymphoblastic
           leukemia (ALL) receiving allogeneic hematopoietic stem cell transplantation (SCT).

      Secondary Objectives:

        -  To determine the effect of rituximab on the incidence of acute graft vs. host disease
           (GVHD).

        -  To determine the efficacy of adding imatinib mesylate post transplant in ALL patients
           with the t(9;22)(q34;q11) cytogenetic abnormality.

        -  To estimate the probability of molecular complete remission at one year for the
           described treatment approach as determined by serial minimal residual disease (MRD)
           monitoring.

        -  To determine the rate of GVHD, engraftment, toxicity, and overall survival (OS) for this
           treatment regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Disease relapse and GVHD are 2 factors that significantly impact survival in ALL patients who
      receive SCT. GVHD occurs when donor cells (graft) attack the stem cell recipient's (host's)
      cells. The term &quot;acute&quot; refers to the time it takes for the GVHD to appear after the
      transplant. This time frame is usually within the first 100 days after the transplant. GVHD
      occurs in up to 50% of patients who receive a transplant.

      Etoposide is a traditional chemotherapy drug that is designed to interfere with the
      production of cancer cells at the DNA and RNA level. Total body irradiation (TBI) uses low
      level radiation to also interfere with the production of cancer cells at the DNA and RNA
      level. The combination of etoposide and TBI is a standard transplant conditioning therapy
      used for ALL patients. Rituximab is a monoclonal antibody that is designed to work against
      cells that express the antigen CD20. In addition, some studies suggest that it may decrease
      the risk of GVHD.

      Before you can start treatment on this study, you will have what are called &quot;screening
      tests&quot;. These tests will help the doctor decide if you are eligible to take part in the
      study. You will have a complete medical history and physical exam, including routine blood
      (2-3 teaspoons) and urine tests. You will have a chest x-ray, heart scan (echocardiogram or
      MUGA scan (Multi Gated Acquisition Scan)), lung function test, and a bone marrow biopsy with
      aspirate to evaluate the status of your disease before transplant. To collect a bone marrow
      biopsy and aspirate, an area of the hip or chest bone is numbed with anesthetic, and a small
      amount of bone marrow and bone is withdrawn through a large needle. A bone marrow core (a
      solid piece from the bone marrow) is also collected through a hollow needle inserted into the
      hip bone. Women who are able to have children must have a negative blood pregnancy test.

      If you are found to be eligible to take part in this study, you will be randomly assigned (as
      in the toss of a coin) to one of 2 treatment groups. Participants in one group will receive
      etoposide and TBI before their transplant. Participants in the other group will receive
      etoposide, TBI, and rituximab before their transplant. There is an equal chance of being
      assigned to either group. You will receive treatment on this study as an inpatient.

      On the 1st day of hospitalization, you will receive fluids by vein through a central venous
      catheter (a plastic tube inserted into a large vein under your collar bone). You will receive
      TBI, once a day for the next 4 days. During TBI, you will lie flat on a table and receive
      radiation beams to all parts of the body, with shielding over certain parts of the body. On
      the following day, you will receive etoposide through the catheter over 4 hours. You will
      then have 2 days of rest, followed by your transplant of stem cells. The stem cells will be
      infused into your vein. The infusion can last from 30 minutes to several hours.

      If you are assigned to the rituximab group, you will also receive rituximab once a week for 4
      weeks by vein over 4-8 hours. The first dose will be given on the first day you receive
      etoposide. If you are receiving a mismatched-related allogeneic stem cell transplant or an
      unrelated allogeneic stem cell transplant, you will also receive Thymoglobulin by vein on the
      3 days before the stem cell infusion. This is given to decrease the risk of GVHD and graft
      rejection in mismatched transplants.

      In addition, you may receive a supportive care drug called palifermin (KepivanceÂ®), which is
      a human keratinocyte growth factor (KGF) produced by recombinant DNA technology in E. coli.
      Its use has been shown to decrease mucositis resulting from high dose chemotherapy used in
      stem cell transplantation. You may receive palifermin for 3 days before starting radiation
      therapy, and for 2 days beginning on the day of your stem cell infusion. You may not receive
      palifermin but you will still receive transplant.

      After you blood counts have normalized following your stem cell transplant, you will start
      taking imatinib mesylate by mouth only if your disease has the Philadelphia chromosome (Ph+
      ALL). Approximately 25-30% of adults with ALL harbor the Philadelphia chromosome. You will
      take it once a day until 1 year after your transplant. Imatinib mesylate should be taken with
      a meal and a glass of water, preferably in the morning. The dose will be gradually increased
      as long as you don't experience severe side effects. If severe side effects occur, imatinib
      will be stopped, either temporarily or permanently.

      You will receive several other medications to help the treatment work and to help decrease
      the risk of infections while your immune system is weak. Tacrolimus and methotrexate will be
      given to decrease the risk of GVHD. The tacrolimus will be started on the day before the
      transplant and will continue for up to 6 months. Tacrolimus is given by vein at first and
      then by mouth when you are able to eat. Methotrexate is given by vein on Days 1, 3, 6, and 11
      after the transplant.

      Sulfamethoxazole (Bactrim) or pentamidine will be given to fight bacteria. Bactrim is given
      by mouth when your blood counts are good. Pentamidine is given by vein when the counts are
      low. Acyclovir will be given at first by vein and then Valtrex (valacyclovir) will be given
      by mouth to decrease the risk of viral infections. Both of these will be given as per
      standard of care. Granulocyte colony-stimulating factor (G-CSF) will be given to help the new
      bone marrow grow. It is given as an injection under the skin after the transplant. It will
      continue until the white blood cells reach an acceptable level. These are all routine
      supportive medications used during bone marrow transplantation. Overall, some of these drugs
      will be given for as long as 6 months or possibly longer. Other medications may be necessary.
      If you are allergic to some of these drugs, changes will be made.

      You will be in the hospital for about 3-4 weeks. You will have checkups every day until you
      are discharged from the hospital. You will then be seen in the outpatient clinic at least 3
      times a week until your blood counts improve. You will be seen by your doctor at least every
      week until 100 days after the bone marrow transplant. You must stay in Houston during this
      time. After 100 days, you will be required to return to Houston every 3 months for tests and
      evaluation over the next 2 years. At these visits, you will have blood (about 2-3 teaspoons)
      collected for routine tests. You will also have a bone marrow biopsy.

      Some participants may need to receive spinal taps with chemotherapy (methotrexate or
      cytarabine given through the spine) several times over the year after transplantation. This
      is only for patients with a previous clinical history of leukemic involvement of the brain or
      high risk of developing leukemia relapse in the brain. The spinal tap is performed in the
      clinic. If you are one of these participants, you will be given local anesthetic at the lower
      back site where a small needle will be inserted in the space between 2 spinal bones. A small
      amount of fluid that bathes the brain (cerebrospinal fluid) will be removed for testing, and
      a small amount of chemotherapy will be given.

      This is an investigational study. The FDA has approved all of the drugs used in this study
      for use in stem cell transplantation. However, their use together in this study is
      experimental. Up to 80 patients will take part in this study. All will be enrolled at UT MD
      Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS)</measure>
    <time_frame>2 Years post transplant or until disease progression or death</time_frame>
    <description>Time from randomization to first progression or death, whichever comes first, measured in months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Incidence of Acute Graft Versus Host Disease During First 100 Days</measure>
    <time_frame>During the first 100 days following transplant</time_frame>
    <description>Number of participants with incidence of acute graft versus host disease (aGVHD) during first 100 days following transplant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Etoposide + Total Body Irradiation + Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etoposide + Total Body Irradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>60 mg/kg IV Daily Over 4 Hours for 1 Day</description>
    <arm_group_label>Etoposide + Total Body Irradiation + Rituximab</arm_group_label>
    <arm_group_label>Etoposide + Total Body Irradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total Body Irradiation</intervention_name>
    <description>3 Gy Daily for 4 Days</description>
    <arm_group_label>Etoposide + Total Body Irradiation + Rituximab</arm_group_label>
    <arm_group_label>Etoposide + Total Body Irradiation</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
    <arm_group_label>Etoposide + Total Body Irradiation + Rituximab</arm_group_label>
    <other_name>Rituxan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with biopsy-proven ALL in remission or relapse.

          -  Adequate renal function, as defined by estimated serum creatinine clearance &gt;50 ml/min
             and/or serum creatinine &lt;1.8 mg/dL.

          -  Adequate hepatic function, as defined by aspartate aminotransferase (AST) or serum
             glutamic oxaloacetic transaminase (SGOT) &lt;3 * upper limit of normal; serum bilirubin
             and alkaline phosphatase &lt;2 * upper limit of normal, or considered not clinically
             significant.

          -  Adequate pulmonary function with Forced Expiratory Volume in One Second (FEV1), forced
             vital capacity (FVC) and Carbon Monoxide Diffusing Capacity (DLCO) at least 45% of
             expected corrected for hemoglobin.

          -  Adequate cardiac function with left ventricular ejection fraction at least 45%. No
             uncontrolled arrhythmias or symptomatic cardiac disease.

          -  Zubrod performance status &lt;2.

          -  Patients must have a related, genotypically human leukocyte antigens (HLA) identical
             donor, or they must have a related or unrelated donor who is at least a 9/10 HLA match
             by high resolution typing.

          -  Female patient must not be pregnant and have negative pregnancy test.

          -  Patient and donor should be willing to participate in the study by providing written
             consent.

        Exclusion Criteria:

          -  Patients with unresolved grade 3 or greater non-hematologic toxicity from previous
             therapy. Patients with grade 2 toxicity will be eligible at the discretion of the
             principal investigator (PI).

          -  Patients with active central nervous system (CNS) disease.

          -  Evidence of acute or chronic active hepatitis or cirrhosis.

          -  Uncontrolled infection, including Human immunodeficiency virus (HIV) or Human
             T-lymphotropic virus Type I (HTLV-1) infection.

          -  Patients greater than 60 years-old.

          -  Prior autologous or allogeneic hematopoietic stem cell transplant.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Partow Kebriaei, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>U.T.M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Cancer Center</description>
  </link>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2007</study_first_submitted>
  <study_first_submitted_qc>January 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2007</study_first_posted>
  <results_first_submitted>January 19, 2012</results_first_submitted>
  <results_first_submitted_qc>April 10, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 7, 2012</results_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Total Body Irradiation</keyword>
  <keyword>Etoposide</keyword>
  <keyword>Rituximab</keyword>
  <keyword>Rituxan</keyword>
  <keyword>TBI</keyword>
  <keyword>ALL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etoposide phosphate</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 05, 2005 to August 08, 2008. All participants were enrolled at UT MD Anderson Cancer Center.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Etoposide + Total Body Irradiation + Rituximab</title>
          <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
        </group>
        <group group_id="P2">
          <title>Etoposide + Total Body Irradiation</title>
          <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Etoposide + Total Body Irradiation + Rituximab</title>
          <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
        </group>
        <group group_id="B2">
          <title>Etoposide + Total Body Irradiation</title>
          <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="23"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS)</title>
        <description>Time from randomization to first progression or death, whichever comes first, measured in months.</description>
        <time_frame>2 Years post transplant or until disease progression or death</time_frame>
        <population>Analysis was by protocol. Participants were randomized between Etoposide + Total body irradiation and Etoposide + Total body irradiation + Rituximab using a Bayesian adaptive algorithm.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoposide + Total Body Irradiation + Rituximab</title>
            <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Etoposide + Total Body Irradiation</title>
            <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS)</title>
          <description>Time from randomization to first progression or death, whichever comes first, measured in months.</description>
          <population>Analysis was by protocol. Participants were randomized between Etoposide + Total body irradiation and Etoposide + Total body irradiation + Rituximab using a Bayesian adaptive algorithm.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="0.95" lower_limit="1" upper_limit="10"/>
                    <measurement group_id="O2" value="14.5" spread="0.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Incidence of Acute Graft Versus Host Disease During First 100 Days</title>
        <description>Number of participants with incidence of acute graft versus host disease (aGVHD) during first 100 days following transplant.</description>
        <time_frame>During the first 100 days following transplant</time_frame>
        <population>Analysis was by protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Etoposide + Total Body Irradiation + Rituximab</title>
            <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
          </group>
          <group group_id="O2">
            <title>Etoposide + Total Body Irradiation</title>
            <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Incidence of Acute Graft Versus Host Disease During First 100 Days</title>
          <description>Number of participants with incidence of acute graft versus host disease (aGVHD) during first 100 days following transplant.</description>
          <population>Analysis was by protocol.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Etoposide + Total Body Irradiation + Rituximab</title>
          <description>Etoposide 60 mg/kg intravenous (IV) Daily Over 4 Hours for 1 Day + Total Body Irradiation (TBI) 3 Gy Daily for 4 Days + Rituximab 375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks</description>
        </group>
        <group group_id="E2">
          <title>Etoposide + Total Body Irradiation</title>
          <description>Etoposide 60 mg/kg IV Daily Over 4 Hours for 1 Day + TBI 3 Gy Daily for 4 Days</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GI Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Transiminitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Venous occlusive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Other (Pain)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Mucositis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>GvHD</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="10"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Neurologic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhagic cystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="10"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Partow Kebriaei, Associate Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <phone>713-792-2648</phone>
      <email>ytdinh@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

